8
Jun, 2020
In 2019, our firm—along with Thomas R. Kline at Kline and Specter—tried the very first punitive damages case against Johnson & Johnson for their drug Risperdal. The drug was originally developed to treat schizophrenia but was aggressively marketed off-label to children with autism and other behavioral disorders. Johnson & Johnson hid the dangerous side effect of its drug from the public, medical community, and F.D.A.
Our client was prescribed Risperdal and developed gynecomastia (female breast growth in boys). Our firm uncovered evidence that Johnson & Johnson knew about the link between their drug and gynecomastia, but didn’t turn it over to the FDA.
After a month-long trial, the jury returned with a verdict of $8 billion—the largest single-plaintiff jury verdict ever won in the Commonwealth of Pennsylvania, and the third largest jury verdict every obtained for an individual in the United States.